1Richardson P. Clinical update: Proteasome inhibitors in hematologic malignancies. Cancer Treat Rev,2003, May; 29 Suppl 1 : 33.
2Richardson P C, Barlogie B, Berenson J. A phase 2 study of bortezomib in relapsed, refractory myeloma. The New England Journal of Medicine, 2003,348(26) :2609.
3Wu K L, V van Wieringen W, Vellenga E. Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice. Haematologica, 2005,90(7):996.
5Dimopoulos M,Anagnostopoulos A, Kyrtsonis M C. Treatment of relapsed or refractory Waldenstrom' s macroglobulinemia with hortezomib. Haematologica,2005,90(12) : 1655.
6Svetomir N. Markovic, Susan M. Geyer, Fitzroy Dawkins. A phase Ⅱ study of bortezomib in the treatment of metastatic malignant melanoma. Cancer, 2005,103(12) :2584.
7Manisha H. shah, Donn young, Hedy L Kindler. Phase Ⅱ study of the Porte Inhibitor Borcezomib ( PS - 341 ) in Patients with Motastatic Nouroendocrine Tumors Clinical Cancer Research, 2004,10: 6111.
6Peng L,Ye X,Zhou Y,et al. Meta-analysis of incidenceand risk of peripheral neuropathy associated with intravenousbortezomib[J]. Support Care Cancer,2015,23(9):2813.
7Perfetti V,Palladini G,Brunetti L,et al. Bortezomibinducedparalytic ileus is a potential gastrointestinal sideeffect of this first-in-class anticancer proteasome inhibitor[J].Eur J Gastroenterol Hepatol,2007,19(7):599.
8Koda Y,Mori T,Shimizu T,et al. Early onset of paralyticileus caused by simultaneous administration of bortezomiband azole antifungals in multiple myeloma patients[J]. RinshoKetsueki,2012,53(8):760.
